| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marie Olsson, Kristina Annerbrink, Finn Bengtsson, Jan Hedner, Elias Eriksso. Paroxetine influences respiration in rats: implications for the treatment of panic disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 14. issue 1. 2004-03-16. PMID:14659984. |
prompted by clinical reports suggesting that the susceptibility to spontaneous as well as co(2)-induced anxiety and hyperventilation is attenuated by serotonin reuptake inhibitors (sris), we undertook the present study in order to explore the possible effect of an sri, paroxetine, on baseline respiration and co(2)-induced hyperventilation in freely moving wistar rats. |
2004-03-16 |
2023-08-12 |
rat |
| Tanya J Fabian, Janet A Amico, Patricia D Kroboth, Benoit H Mulsant, Sharon E Corey, Amy E Begley, Salem G Bensasi, Elizabeth Weber, Mary Amanda Dew, Charles F Reynolds, Bruce G Polloc. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Archives of internal medicine. vol 164. issue 3. 2004-03-12. PMID:14769630. |
older depressed patients are at high risk for development of hyponatremia after initiation of the selective serotonin reuptake inhibitor paroxetine, despite clinical monitoring and preventive management. |
2004-03-12 |
2023-08-12 |
Not clear |
| John H Greist, Borwin Bandelow, Eric Hollander, Donatella Marazziti, Stuart A Montgomery, David J Nutt, Ahmed Okasha, Richard P Swinson, Joseph Zoha. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS spectrums. vol 8. issue 8 Suppl 1. 2004-03-11. PMID:14767394. |
pharmacologic treatment options include the tricyclic antidepressant clomipramine and the selective serotonin reuptake inhibitors (ssris) citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. |
2004-03-11 |
2023-08-12 |
Not clear |
| Christer Allgulander, Borwin Bandelow, Eric Hollander, Stuart A Montgomery, David J Nutt, Ahmed Okasha, Mark H Pollack, Dan J Stein, Richard P Swinso. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS spectrums. vol 8. issue 8 Suppl 1. 2004-03-11. PMID:14767398. |
paroxetine is the first of the selective serotonin reuptake inhibitors (ssris) to receive us approval for the treatment of gad. |
2004-03-11 |
2023-08-12 |
Not clear |
| Tracy M Felton, Tommy B Kang, Stephan Hjorth, Sidney B Auerbac. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn-Schmiedeberg's archives of pharmacology. vol 367. issue 3. 2004-02-24. PMID:12644903. |
during the lights-off period, paroxetine and duloxetine increased 5-ht in the diencephalon approximately 300 and approximately 200%, respectively. |
2004-02-24 |
2023-08-12 |
rat |
| Tracy M Felton, Tommy B Kang, Stephan Hjorth, Sidney B Auerbac. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn-Schmiedeberg's archives of pharmacology. vol 367. issue 3. 2004-02-24. PMID:12644903. |
during the lights-on period, paroxetine and duloxetine each increased 5-ht approximately 400% in the diencephalon. |
2004-02-24 |
2023-08-12 |
rat |
| Tracy M Felton, Tommy B Kang, Stephan Hjorth, Sidney B Auerbac. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn-Schmiedeberg's archives of pharmacology. vol 367. issue 3. 2004-02-24. PMID:12644903. |
in the frontal cortex, both paroxetine and duloxetine increased 5-ht approximately 200%. |
2004-02-24 |
2023-08-12 |
rat |
| Gary R Morrow, Jane T Hickok, Joseph A Roscoe, Richard F Raubertas, Paul L R Andrews, Patrick J Flynn, Harry E Hynes, Tarit K Banerjee, Jeffrey J Kirshner, David K Kin. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. vol 21. issue 24. 2004-02-13. PMID:14673053. |
this randomized clinical trial tested whether paroxetine, a selective serotonin reuptake inhibitor antidepressant known to modulate brain serotonin, would reduce fatigue in cancer patients and whether any reduction was related to depression. |
2004-02-13 |
2023-08-12 |
Not clear |
| C Lindsay DeVan. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. The Journal of clinical psychiatry. vol 64 Suppl 18. 2004-02-12. PMID:14700450. |
these newer antidepressants include the selective serotonin reuptake inhibitors (ssris) citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline; venlafaxine, a serotonin-norepinephrine reuptake inhibitor; and bupropion, a selective norepinephrine and dopamine reuptake inhibitor. |
2004-02-12 |
2023-08-12 |
Not clear |
| Youssef Sari, Feng C Zho. Serotonin and its transporter on proliferation of fetal heart cells. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. vol 21. issue 8. 2004-02-09. PMID:14659992. |
our study indicated that the blockade of 5-ht uptake by paroxetine decreased the number of brdu-im cells and mf20-im cells. |
2004-02-09 |
2023-08-12 |
Not clear |
| Marcel D Waldinger, Aeilko H Zwinderman, Berend Olivie. Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. Journal of clinical psychopharmacology. vol 23. issue 5. 2004-01-30. PMID:14520123. |
a double-blind, fixed-dose study in healthy men with lifelong early ejaculation was performed to evaluate potential differences in their effects on ejaculation latency, between clinically relevant doses of the selective serotonin reuptake inhibitor paroxetine and the noradrenergic and specific serotonergic antidepressant mirtazapine. |
2004-01-30 |
2023-08-12 |
Not clear |
| Charles B Nemeroff, Michael J Owen. Neuropharmacology of paroxetine. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566196. |
paroxetine is a potent and selective serotonin reuptake inhibitor (ssri) with some neuropharmacologic properties unique among this class of compounds. |
2004-01-28 |
2023-08-12 |
human |
| Charles B Nemeroff, Michael J Owen. Neuropharmacology of paroxetine. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566196. |
the findings of early in vitro studies demonstrated the potency of paroxetine at inhibiting 5-ht uptake in rat synaptosomes. |
2004-01-28 |
2023-08-12 |
human |
| Charles B Nemeroff, Michael J Owen. Neuropharmacology of paroxetine. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566196. |
paroxetine also has been shown to be a potent and selective inhibitor of the human serotonin transporter (sert) and has recently been demonstrated to have moderate affinity for the norepinephrine transporter (net). |
2004-01-28 |
2023-08-12 |
human |
| Charles B Nemeroff, Michael J Owen. Neuropharmacology of paroxetine. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566196. |
paroxetine administration in laboratory animals has been shown to be associated with decreased sert density and function, maintenance of normal firing rates and release of 5-ht, and increased activation of postsynaptic 5-ht receptors. |
2004-01-28 |
2023-08-12 |
human |
| Clinton Kilt. In vivo neuroimaging correlates of the efficacy of paroxetine in the treatment of mood and anxiety disorders. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566198. |
the findings of neuroimaging studies of paroxetine will be placed into perspective for a better understanding of the interaction of this selective serotonin reuptake inhibitor (ssri) with the serotonergic and noradrenergic systems in the brain that mediate clinical efficacy. |
2004-01-28 |
2023-08-12 |
Not clear |
| C Lindsay DeVan. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566199. |
considerations of the pharmacokinetic properties of paroxetine support a rationale for the development of new dosage forms that maintain the efficacy yet improve the tolerability profile of the selective serotonin reuptake inhibitors. |
2004-01-28 |
2023-08-12 |
Not clear |
| Martin B Kelle. Paroxetine treatment of major depressive disorder. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566200. |
paroxetine is a widely studied selective serotonin reuptake inhibitor (ssri) with evidence for efficacy and safety that is supported by a large body of published literature. |
2004-01-28 |
2023-08-12 |
Not clear |
| Jonathan R T Davidso. Treatment of posttraumatic stress disorder: the impact of paroxetine. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566203. |
the efficacy and tolerability of the selective serotonin reuptake inhibitors (ssris), paroxetine, sertraline, and fluoxetine, also have been demonstrated in clinical trials. |
2004-01-28 |
2023-08-12 |
Not clear |
| Philip T Nina. Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine. Psychopharmacology bulletin. vol 37 Suppl 1. 2004-01-28. PMID:14566204. |
randomized, placebo-controlled trials indicate acute and long-term efficacy of potent selective serotonin reuptake inhibitors (ssris), such as paroxetine. |
2004-01-28 |
2023-08-12 |
Not clear |